COMPANY

Apnimed

HQ: Cambridge, MA source · apnimed.com ↗

Clinical Phase 3

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Obstructive Sleep Apnea OSA - Obstructive Sleep Apnea Hypertension AD109 AD504 AD036 AD113 AD313 AD182

13Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $25M (Form D filed Mar 27, 2026). SEC Form D 0001745648-26-000001 (Mar 27, 2026)
Evidence (1 event)
- Mar 27, 2026 · SEC Form D 0001745648-26-000001
  Name of Issuer: Apnimed, Inc.; CIK: 1745648; Address: Cambridge, MA; Submission type: D; Filing date: 2026-03-27; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 24999994; Total Amount Sold: 24999994; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 3, 2024 Trial start Phase 3: Continuation Protocol for Obstructive Sleep Apnea (OSA) source ↗
May 20, 2024 Trial start Phase 2: Study That Tests AD109 in Patients Taking GLP-1 Drugs source ↗
Sep 16, 2023 Trial start Phase 3: Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) source ↗
Aug 28, 2023 Trial start Phase 3: Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) source ↗
Apr 28, 2023 Trial start Phase 2: AD816 Crossover Study source ↗
Nov 29, 2021 Trial start Phase 2: Parallel Arm Trial of AD109 and AD504 In Patients With OSA source ↗
Oct 19, 2021 Trial start Phase 1/Phase 2: Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) source ↗
Jul 31, 2021 Trial start Phase 2: Trial of AD113 and Atomoxetine in OSA Patients With Hypertension source ↗
Dec 22, 2020 Trial start Phase 2: AD109 Dose Finding in Mild to Moderate OSA source ↗
Dec 1, 2020 Trial start Phase 2: Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea source ↗
Oct 27, 2020 Trial start Phase 2: Crossover Trial of AD109 in Obstructive Sleep Apnea source ↗
Jul 15, 2020 Trial start Phase 2: Crossover Trial of AD036 in Obstructive Sleep Apnea source ↗
Mar 7, 2019 Trial start Phase 2: Trial of AD036 in Obstructive Sleep Apnea source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT05813275	Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)	Phase 3	Completed	Sep 16, 2023	Mar 10, 2025 (actual)
NCT05071612	Parallel Arm Trial of AD109 and AD504 In Patients With OSA	Phase 2	Completed	Nov 29, 2021	Jul 20, 2022 (actual)
NCT05811247	Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)	Phase 3	Completed	Aug 28, 2023	May 7, 2025 (actual)
NCT06566820	Continuation Protocol for Obstructive Sleep Apnea (OSA)	Phase 3	Enrolling by invitation	Jul 3, 2024	Jun 30, 2026 (estimated)
NCT06400615	Study That Tests AD109 in Patients Taking GLP-1 Drugs	Phase 2	Completed	May 20, 2024	Dec 26, 2024 (actual)
NCT05793684	AD816 Crossover Study	Phase 2	Completed	Apr 28, 2023	Nov 9, 2023 (actual)
NCT04445688	Crossover Trial of AD036 in Obstructive Sleep Apnea	Phase 2	Completed	Jul 15, 2020	Dec 1, 2020 (actual)
NCT04905979	Trial of AD113 and Atomoxetine in OSA Patients With Hypertension	Phase 2	Completed	Jul 31, 2021	Jan 31, 2023 (actual)
NCT05101122	Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)	Phase 1/Phase 2	Completed	Oct 19, 2021	Apr 18, 2022 (actual)
NCT04580394	Crossover Trial of AD109 in Obstructive Sleep Apnea	Phase 2	Completed	Oct 27, 2020	May 28, 2021 (actual)
NCT03845023	Trial of AD036 in Obstructive Sleep Apnea	Phase 2	Completed	Mar 7, 2019	Oct 23, 2019 (actual)
NCT04631107	AD109 Dose Finding in Mild to Moderate OSA	Phase 2	Completed	Dec 22, 2020	May 31, 2021 (actual)
NCT04645524	Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea	Phase 2	Completed	Dec 1, 2020	Sep 1, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-03-27 Raise Private raise (SEC Form D): $25.0M sold; issuer “Apnimed, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-12-08 Raise Private raise, amended notice (SEC Form D/A): $35.0M sold; issuer “Apnimed, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-10-01 Raise Private raise, amended notice (SEC Form D/A): $35.0M sold; issuer “Apnimed, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-09-24 Raise Private raise (SEC Form D): $23.0M sold; issuer “Apnimed, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-04-24 Raise Private raise (SEC Form D): $16.5M sold; issuer “Apnimed, Inc.”. Verified from the SEC filing. SEC filing ↗